The positive early progression-free survival trends for GRANITE recipients, especially in a high-risk group, suggest that the drug could have significant efficacy. This could lead to increased investor confidence in Gritstone bio's pipeline and potentially drive up the stock price in the short term as the market reacts to these positive developments.